MX2022003213A - Metodos de uso para activadores de canal kv7. - Google Patents

Metodos de uso para activadores de canal kv7.

Info

Publication number
MX2022003213A
MX2022003213A MX2022003213A MX2022003213A MX2022003213A MX 2022003213 A MX2022003213 A MX 2022003213A MX 2022003213 A MX2022003213 A MX 2022003213A MX 2022003213 A MX2022003213 A MX 2022003213A MX 2022003213 A MX2022003213 A MX 2022003213A
Authority
MX
Mexico
Prior art keywords
methods
compounds
pharmaceutically acceptable
channel activators
pharmaceutical compositions
Prior art date
Application number
MX2022003213A
Other languages
English (en)
Inventor
Michael E Bozik
Steven Dworetzky
Kelly Picchione
Gregory Hebrank
Jr Thomas Petzinger
Original Assignee
Knopp Biosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knopp Biosciences Llc filed Critical Knopp Biosciences Llc
Publication of MX2022003213A publication Critical patent/MX2022003213A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

En este documento se proporcionan compuestos y composiciones farmacéuticas que comprenden una cantidad terapéuticamente efectiva de tales compuestos, o sales farmacéuticamente aceptables, y un excipiente farmacéuticamente aceptable, y métodos para tratar enfermedades o trastornos de desarrollo neurológico (NDD) y encefalopatía epiléptica y del desarrollo (DEE), que comprenden administrar tales compuestos, o sales farmacéuticamente aceptables, y composiciones farmacéuticas, a pacientes pediátricos.
MX2022003213A 2019-09-17 2020-09-17 Metodos de uso para activadores de canal kv7. MX2022003213A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962901621P 2019-09-17 2019-09-17
US201962945300P 2019-12-09 2019-12-09
PCT/US2020/051171 WO2021055538A1 (en) 2019-09-17 2020-09-17 Methods of use for kv7 channel activators

Publications (1)

Publication Number Publication Date
MX2022003213A true MX2022003213A (es) 2022-05-24

Family

ID=74884349

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003213A MX2022003213A (es) 2019-09-17 2020-09-17 Metodos de uso para activadores de canal kv7.

Country Status (12)

Country Link
US (1) US20220323417A1 (es)
EP (1) EP4031548A4 (es)
JP (1) JP2022548631A (es)
KR (1) KR20220079863A (es)
CN (1) CN114728961A (es)
AU (1) AU2020350614A1 (es)
BR (1) BR112022004847A2 (es)
CA (1) CA3150501A1 (es)
CL (1) CL2022000639A1 (es)
IL (1) IL291318A (es)
MX (1) MX2022003213A (es)
WO (1) WO2021055538A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3093976A1 (en) * 2018-03-19 2019-09-26 Michael E. Bozik Kv7 channel activators compositions and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3572405T (lt) * 2014-09-12 2023-10-25 Biohaven Therapeutics Ltd. Benzoimidazol-1,2-ilo amidai, kaip kv7 kanalų aktyvatoriai
CA3093976A1 (en) * 2018-03-19 2019-09-26 Michael E. Bozik Kv7 channel activators compositions and methods of use

Also Published As

Publication number Publication date
IL291318A (en) 2022-05-01
US20220323417A1 (en) 2022-10-13
CA3150501A1 (en) 2021-03-25
CL2022000639A1 (es) 2022-11-04
WO2021055538A1 (en) 2021-03-25
EP4031548A4 (en) 2023-10-18
KR20220079863A (ko) 2022-06-14
EP4031548A1 (en) 2022-07-27
BR112022004847A2 (pt) 2022-06-07
CN114728961A (zh) 2022-07-08
AU2020350614A1 (en) 2022-03-31
JP2022548631A (ja) 2022-11-21

Similar Documents

Publication Publication Date Title
MX2021007970A (es) Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo.
CO6361928A2 (es) Modulares de aril metil benzoquinazolinona alostericos positivos del receptor m1
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
MD20140059A2 (en) Substituted 4-phenyl-pyridines for the treatment of NK-1 receptor related diseases
PH12020550503A1 (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
EP3970712A3 (en) Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
MX2013012588A (es) Inhibidores de cinasa.
MX2021010568A (es) Leucina, acetilleucina y analogos relacionados para el tratamiento de enfermedades.
JOP20210324A1 (ar) مشتقات من 2h-indazole واستخدامها في علاج مرض
TN2020000161A1 (en) CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGIuR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
WO2012142615A3 (en) Auranofin and auranofin analogs useful to treat proliferative disease and disorders
MX2022000143A (es) Metodos novedosos.
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
CR20210630A (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
MX2021003842A (es) Terapia combinada para el tratamiento del cancer.
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
IL307992A (en) Parasitic formulations containing isoxazoline and methods for treating blepharitis
MX2022003213A (es) Metodos de uso para activadores de canal kv7.
EA201171087A1 (ru) СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ
WO2020128614A8 (en) Method for treating interstital lung disease
MX2020004667A (es) Compuestos, composiciones y metodos para el tratamiento de trastornos oculares y enfermedades cutaneas.
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
PH12018500469A1 (en) Sulfonamide compounds as voltage-gated sodium channel modulators